Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation investigational neuromodulator product, DaxibotulinumtoxinA for Injection. We are building a premium category in facial aesthetics, which is focused on differentiated and improved outcomes, a compelling value proposition and an elevated experience for HCPs and patients.
DaxibotulinumtoxinA for Injection has been evaluated for the treatment of glabellar (frown) lines in the Phase 3 SAKURA program, the largest aesthetic neuromodulator clinical program to date. In the Phase 3 pivotal program, the median time to loss of none or mild wrinkle severity was 24 weeks and the median time to return to baseline wrinkle severity was approximately 28 weeks. Duration is the single most important unmet need in the neuromodulator market where the consumer experience has remained largely unchanged since these types of treatments were first introduced over 30 years ago.
We are also evaluating DaxibotulinumtoxinA for Injection in forehead lines and lateral canthal lines (crow’s feet). Additionally, Revance entered a U.S. distribution agreement with TEOXANE SA (TEOXANE®), making Revance the exclusive commercialization partner of the Swiss company’s modern Resilient Hyaluronic Acid® (RHA®) technology.
Revance is positioned to be an innovation leader not only in aesthetics but in therapeutics. DaxibotulinumtoxinA for Injection is also being studied in cervical dystonia, adult upper limb spasticity, and plantar fasciitis, with plans to study migraine.
We believe in leaving bureaucracy behind. We value speed, audacity, grit and empathy, and empower our teams to reimagine the status quo.